Edge Therapeutics to Present at Rodman & Renshaw’s 13th Annual Healthcare Conference

NEWARK, NJ--(Marketwire - September 07, 2011) - Edge Therapeutics, Inc., a biopharmaceutical company developing novel implantable technology for direct delivery of proven therapeutic compounds to the site of brain injury, will be a presenting company at the Rodman & Renshaw 13th Annual Healthcare Conference to be held in New York City from September 11-13, 2011 at the Waldorf-Astoria. Brian Leuthner, chief executive officer, is scheduled to present on Tuesday, September 13th, at 12:05 p.m. in the Metropolitan West conference room.

Mr. Leuthner will provide a brief overview of the company’s exciting product pipeline, its development status and upcoming milestones. In addition, Mr. Leuthner will be available for one-on-one meetings throughout the day, and interested parties may schedule meetings through their Rodman & Renshaw representative.

About Edge Therapeutics

Edge Therapeutics is a hospital-focused biopharmaceutical company that uses a novel, site-specific and sustained release-microparticle technology platform to develop products for acute, and fatal or debilitating neurological conditions that currently have no effective therapies. Edge works with some of the world’s foremost scientists from leading academic research centers to develop proprietary and novel formulations of known active drugs for direct therapeutic delivery to the site of injury in the brain. The company’s patent-protected bioabsorbable microparticle formulations release drugs locally and consistently at therapeutic concentrations in the brain, which maximizes therapeutic activity while avoiding treatment-limiting systemic side effects seen with oral and intravenous delivery. The technology platform is the basis of Edge’s pipeline of drugs in therapeutic areas such as spontaneous brain hemorrhage, traumatic brain injury and brain surgery. The lead products, NimoGel and NimoVent, are microparticle formulations of the calcium channel blocker nimodipine. These drugs are being developed to prevent delayed complications after subarachnoid hemorrhage (where today oral- or i.v.-administered nimodipine is employed but in suboptimal concentrations due to the generation of systemic side effects). Phase 2 studies for both NimoGel and NimoVent are planned for 2012.

For more information on Edge Therapeutics, Inc., please visit www.edgetherapeutics.com.